A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma
- 24 September 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (13) , 2730-2732
Abstract
Prediagnostic serum concentration of soluble CD30 (sCD30), a marker for chronic B-cell stimulation, has been associated with increased risk of developing AIDS-related non-Hodgkin lymphoma (NHL) in a recent study of HIV+ patients. To investigate among healthy persons whether serum sCD30 is associated with NHL risk, we carried out a nested case-control study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. There was a strong dose-response relationship between prediagnostic sCD30 concentration and NHL risk among 234 cases and 234 individually matched controls (odds ratio [95% confidence interval] for second, third, and fourth quartiles vs first quartile: 1.4 [0.8-2.6], 2.2 [1.2-4.1], 4.1 [2.2-7.8]; Ptrend < .001), which persisted among cases diagnosed 6 to 10 years after providing a blood sample. Given that a similar relationship has been observed among HIV+ patients, our findings suggest that chronic B-cell stimulation may be an important mechanism involved in B-cell lymphomagenesis among severely immunocompromised and healthy populations alike.Keywords
This publication has 13 references indexed in Scilit:
- CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma CellsThe American Journal of Pathology, 2008
- Non-Hodgkin Lymphoma2006
- Deciphering CD30 ligand biology and its role in humoral immunityImmunology, 2006
- Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001Blood, 2006
- Elevated Serum Soluble CD30 Precedes the Development of AIDS-Associated Non-Hodgkin’s B Cell LymphomaTumor Biology, 2006
- The epidemiology of non-Hodgkin's lymphomaOncogene, 2004
- Serologic Assessment of Type 1 and Type 2 Immunity in Healthy Japanese AdultsCancer Epidemiology, Biomarkers & Prevention, 2004
- The role of CD30 in the pathogenesis of haematopoietic malignanciesCurrent Opinion in Pharmacology, 2004
- Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphomaHematology/Oncology Clinics of North America, 2003
- An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapyClinical and Experimental Immunology, 2001